Patent Grant
11771841
The present disclosure relates generally to systems for mixing and to mixing syringes. More specifically, embodiments of the present disclosure relate to mixing syringes operable to store and selectively mix contents between two syringes, and which include a valve assembly to separate syringe contents at least prior to mixing operations.
It is known to store drugs and therapeutic agents in a lyophilized or powdered form. For example, because of stability and shelf-life factors, therapeutic proteins are often formulated as powders that must be reconstituted, e.g. in a liquid or flowable medium or material, prior to injection. Similarly, it is known to store components of certain complex drug formulations (whether liquid or solid) in separate containers for reasons related to stability or reactivity of the components, where the contents of the separate containers must be mixed prior to injection. Related methods and systems have been provided to allow users and healthcare professionals to combine and formulate a drug just prior to administration. Known systems and methods include single-barrel systems such as those shown and described in U.S. Pat. No. 9,592,343 to Shetty et al., which is hereby incorporated by reference. Such systems and methods generally comprise two or more contents initially separated by a valved stopper or similar member and wherein repetitive motion of the stopper and associated plunger rod is operable to mix syringe contents and subsequently eject a solution from the device. Dual-syringe systems and methods are also known, such as those shown and described in U.S. Pat. No. 9,220,577 to Jessop et al, which is hereby incorporated by reference in its entirety. Dual-syringe systems generally comprise a first material provided in a first syringe barrel and a second material provided in a second syringe barrel. The two syringe barrels of such systems can be connected to one another by joining their distal outlets such that the two syringes are in fluid communication. Sequential activation of the plunger rods of each syringe is then operable to force contents between the two syringes and provide a mixing action.
However, various known systems and devices suffer from drawbacks including, for example, a high level of pre-administration steps that can increase the likelihood of user error, improper mixing, dosing errors, and unwanted migration or leakage of syringe contents. For example, existing devices may initially be provided to a user as two separate syringes, each housing separate contents, e.g. a liquid or flowable component and a lyophilizate or other form of therapeutic agent, in order to reduce or eliminate the risk of unwanted migration of the liquid or flowable component from a first syringe to the lyophilizate or other form of therapeutic agent of a second syringe during storage. However, the use of such a device requires additional steps, including assembly steps, before mixing and administration can occur. Conversely, single-barrel systems reduce or eliminate the need to connect or assemble components prior to mixing but provide for the possibility that a liquid or flowable component can migrate or leak into a volume containing lyophilizate or other form of therapeutic agent prior to the desired time for mixing. Single-barrel systems are also restricted by the viscosity of syringe contents and are not suitable for all applications.
Accordingly, there has been a long-felt and unmet need to provide methods and systems for mixing drugs and therapeutic agents while reducing the risks and drawbacks of methods and systems of the prior art.
It is an object of the present disclosure to provide methods and systems for mixing contents while reducing the number of required administration steps. It is also an object of the present disclosure to provide methods and systems for mixing contents which reduce the risk of adverse user errors and mistakes associated with administration of said contents. It is a further object of the present disclosure to provide methods and systems for mixing the contents of containers, chambers, or syringes while preventing or reducing the risk of unwanted migration, combination, mixing, etc. of materials. Furthermore, it is an object of the present disclosure to provide methods and systems for mixing portions of a pharmaceutical composition or formulation comprising an active pharmaceutical ingredient (API) useful in the treatment in a disease or disorder in a patient. It is yet a further object of the present disclosure to provide methods and systems for mixing materials of a pharmaceutical formulation comprising lyophilized leuprolide or a pharmaceutically acceptable salt thereof (e.g. leuprolide acetate) and a biodegradable polymer-solvent system useful in the treatment of a disease or a disorder, including a cancer, including but not limited to prostate cancer or breast cancer.
In various embodiments, mixing syringe systems are provided comprising a first syringe, a second syringe, and a syringe coupler or coupling device. The syringe coupler is contemplated as comprising a device that is operable to interconnect the first and second syringe and to segregate contents of the two syringes during shipping and storage, for example, and which provides a reliable seal or closure element to achieve segregation while also obviating the need for users to assemble the syringes prior to mixing. In some embodiments, a first syringe, a second syringe, and a syringe coupler are provided and the components are interconnected for shipping and storage such that a user need not assemble components prior to mixing for subsequent administration of a drug or a therapeutic agent.
While various embodiments of the present disclosure contemplate a first syringe comprising first syringe contents (e.g. fluid) and a second syringe comprising second syringe contents (e.g. solid(s)), further embodiments contemplate that a first syringe may be initially devoid of material and a second syringe is provided that comprises one or more contents that require mixing. It should be recognized that various storing, mixing, and reconstitution applications are contemplated by embodiments of the present disclosure and inventive aspects of the disclosure are not limited to any particular intended use or application.
In some embodiments, a user-activated element is provided with systems of the present disclosure. The user-activated element preferably comprises an irreversible “one-way” feature wherein the user is allowed to activate the element and move the element from a first state to a second state but cannot return the element to the first state. For example, in some embodiments, a valve activation element is provided that is operable to be moved by a user from a first position (e.g. a sealed position) to a second position (e.g. a flow-enabled position) but cannot perform a reverse operation to close the element (i.e. the operation from a first position to a second position is irreversible).
In various embodiments, a syringe coupler or hub member is provided wherein at least one syringe can be connected to the syringe coupler and wherein removal of the syringe from the coupler is prevented or impeded. In some embodiments, for example, a first syringe comprising a polymer is operable to be connected and/or disconnected from a syringe coupler prior to activation or adjustment of the syringe coupler. Once the syringe coupler has been activated (e.g. a fluid flow path in the coupler has been opened), the first syringe is no longer capable of being removed. Preventing removal of at least one syringe from the coupler is useful, for example, to guide the user in the use of a second syringe (and only a second syringe) during administration once mixing is completed.
In various embodiments, systems and devices of the present disclosure comprise an elastomer element operable to seal a fluid pathway between first and second syringes. It is contemplated that devices and systems of the present disclosure are suitable for housing various materials and agents including, but not limited to: drugs and other therapeutic agents (in solid, e.g. lyophilized, or semi-solid or liquid/fluid form); liquid or flowable diluents, excipients or solvent systems; solvent systems further comprising co-solvents; polymer-solvent systems; polymer-solvent systems comprising co-polymers; or any combination thereof. A non-limiting example of a solvent suitable for use in the systems and devices of the present disclosure is N-methyl-2-pyrrolidone (NMP), a liquid organic solvent with known volatility capable of producing gaseous vapor, which can circulate within enclosed spaces such as an inner plastic tray enclosure or outer carton commonly associated with a drug products packaging. While various embodiments of the present disclosure contemplate packaging and sealing elements with a secure seal for various materials and uses, some embodiments contemplate and provide systems that securely house NMP or similar solvent and separate the NMP from a solid such as lyophilized leuprolide acetate. If NMP is allowed to migrate into a storage or housing area of the solid, the active pharmaceutical ingredient could be degraded such that shelf life and overall stability of the materials are reduced. It should be recognized that other materials and applications stand to benefit from storage and sealing elements that provide a secure seal (at least prior to mixing) and the present disclosure is not limited to NMP and/or leuprolide acetate. Embodiments of the present disclosure as shown and described herein provide for reliable physical separation and prevention of migration of vapor, liquids, and solids.
Various elastomers (e.g. santoprene) are contemplated for use with valve assemblies of embodiments of the present disclosure to inhibit or prevent liquid or gaseous solvent transmission. In further embodiments, it is contemplated that plastic components (including plastic-on-plastic components) are provided that create sufficient sealing to prevent liquid or gaseous solvent transmission between syringes and other components of the present disclosure.
While various materials are contemplated for use with embodiments of the present disclosure, preferred embodiments of the present disclosure contemplate the use of materials that are operable to withstand and are compatible with terminal manufacturing sterilization using, e.g., e-beam irradiation, gamma radiation, x-ray techniques, and ethylene oxide sterilization.
In one embodiment, a syringe-to-syringe mixing system is provided that comprises a first syringe barrel comprising a hollow body defining an internal chamber, and the hollow body has a proximal end and a distal dispensing end with an outlet. The system also comprises a second syringe barrel comprising a hollow body defining an internal chamber, the hollow body of the second syringe barrel having a proximal end and a distal dispensing end with an outlet. The first syringe barrel and the second syringe barrel each comprise a plunger slidably disposed within the syringe barrel for applying pressure to a content housed within the internal chambers. A syringe coupler is provided that is operable to receive the first syringe barrel and the second syringe barrel. The syringe coupler comprises a displaceable seal that comprises a flow port that is offset from the outlet of at least one of the first syringe barrel and the second syringe barrel when the displaceable seal is provided in a first position, and wherein the flow port is aligned with the outlet of the first syringe barrel and the second syringe barrel when the displaceable seal is provided in a second position.
In another embodiment, a syringe-to-syringe mixing system is provided that comprises a first syringe barrel with a hollow body, the hollow body having a proximal end and a distal dispensing end with an outlet, and a second syringe barrel with a hollow body and an outlet, the second syringe comprising a distal dispensing end with an outlet. The first syringe barrel and the second syringe barrel each comprise a plunger slidably disposed within the syringe barrel for applying pressure to a material housed within the internal chambers. A valve assembly is provided that is operable to receive the first syringe barrel and the second syringe barrel. The valve assembly comprises a displaceable user-interface operable to receive a force from a user and transmit the force to a displaceable seal, and wherein the displaceable user-interface is moveable in a direction substantially perpendicular to a longitudinal axis of at least one of the first syringe barrel and the second syringe barrel.
In various embodiments, methods of mixing syringe contents and preparing therapeutic agents are provided. In one embodiment, a method of preparing a therapeutic agent is provided that comprises providing a first syringe barrel and a second syringe barrel. The first syringe barrel and the second syringe barrel each comprise a plunger slidably disposed therein for applying pressure to a material housed within the syringe barrels. A syringe coupler is provided that is operable to receive the first syringe barrel and the second syringe barrel, and the syringe coupler comprises a user-interface and a displaceable seal. The method comprises securing at least one of the first syringe barrel and the second syringe barrel to the syringe coupler, applying a force to the user-interface to move the displaceable seal from a first position to a second position, and applying force to the plunger of the first syringe barrel and the second syringe barrel in an alternating manner to mix contents of the first syringe barrel and the second syringe barrel.
The Summary of the Invention is neither intended nor should it be construed as being representative of the full extent and scope of the present disclosure. The present disclosure is set forth in various levels of detail in the Summary as well as in the attached drawings and the Detailed Description and no limitation as to the scope of the present disclosure is intended by either the inclusion or non-inclusion of elements, components, etc. in this Summary. Additional aspects of the present disclosure will become more readily apparent from the Detailed Description, particularly when taken together with the drawings.
Those of skill in the art will recognize that the following description is merely illustrative of the principles of the disclosure, which may be applied in various ways to provide many different alternative embodiments. This description is made for illustrating the general principles of the teachings of this disclosure and is not meant to limit the inventive concepts disclosed herein.
The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate embodiments of the disclosure and together with the general description of the disclosure given above and the detailed description of the drawings given below, serve to explain the principles of the disclosure.
It should be understood that the drawings are not necessarily to scale. In certain instances, details that are not necessary for an understanding of the disclosure or that render other details difficult to perceive may have been omitted. It should be understood, of course, that the disclosure is not necessarily limited to the particular embodiments illustrated herein.
As shown in
An activation force upon the displaceable member 24 is operable to move the displaceable member from a first position (
Unwanted NMP migration (i.e. unintended migration prior to mixing) has been recognized as providing various complications including, for example, degrading or destroying shelf-life of contents. It is an object of various embodiments of the present disclosure to reduce or eliminate the risks of unwanted NMP migration while storing NMP and a drug lyophilizate in close proximity prior to mixing.
The contents of the first and second syringes 42, 44 may be mixed to formulate a solution or suspension for administration as shown and described herein. The embodiment of
Each syringe 42, 44 comprises a barrel having an internal volume, proximal ends for receiving a plunger rod (not shown in
As shown in
As shown in
A surface of the guide member 56 comprises a channel 72 (
In a first position prior to activation, the ramp-like projection 60 and the projection 75 of the displaceable member 50 are provided in communication with a rotatable Luer lock member 58 to prevent rotation thereof. In a second position subsequent to activation, the projection 60 of the displaceable member 50 is displaced into the channel 72 of guide member 56 while projection 75 of the displaceable member is displaced into the recessed area 73 (
As shown in
Systems, devices and methods of the present disclosure are not limited to any particular therapeutic agent(s), solution(s), suspension(s), gas, or a combination thereof. In some embodiments, for example, it is contemplated that that one or more non-lyophilized materials are provided in syringes of the present disclosure. In some embodiments, a gas (e.g. Cobalt gas) is provided in a syringe for mixing with contents of a second syringe. Such embodiments, including others, complete that mixing syringe systems of the present disclosure comprise gas-impermeable materials to prevent gas permeation and migration. However, in certain preferred embodiments, a first syringe 42 is initially provided with a liquid formulation component such as a polymer-solvent system and a second syringe is provided with an API, which may, in some non-limiting instances, be present as a lyophilized power. In such embodiments, the contents are stored separately with each respective syringe which are interconnected to the syringe coupler with the displaceable member provided in the first position (
The displaceable member 50 comprises first and second projections 62a, 62b that are operable to be outwardly displaced upon downward movement of the displaceable member. The first and second projections 62a, 62b are secured within the recesses 74a, 74b of the guide member 56 and move inwardly based on their inherent material properties and elasticity. The placement of the first and second projections 62a, 62b within or partially within the recesses 74a, 74b of the guide member 56 prevent or inhibit a return movement of the displaceable member 50 back to the first position.
In certain embodiments, proximal ends 120, 122 of the components are operable to receive a syringe. An axial compression force on the syringe(s) (not shown in
It is further contemplated that the embodiments of
In certain embodiments, proximal ends 140, 142 of the components are operable to receive a syringe. An axial compression force on the syringe(s) (not shown in
It is further contemplated that the embodiments of
Although not shown in
The contents of the first and second syringes 152, 154 may be mixed to formulate a solution or suspension for administration as shown and described herein. The embodiment of
Each syringe 152, 154 comprises a barrel having an internal volume, proximal ends for receiving a plunger rod (not shown in
The displaceable member 158 comprises a user-interface 160 that is operable to be contacted by and receive a force from a user and a male extension 162 for receiving the second syringe 154. The syringe coupler 156 further comprises a guide member 168 within which the displaceable member is provided. The guide member 168 comprises a user-interface 178 (
As shown in
As shown in
A surface of the guide member 168 comprises a recessed area 182 in which the projection 170 of the displaceable member 158 (
The second position further comprises a position wherein a fluid flow channel is created. Specifically, a sealing element 164 provided within the displaceable member 158 is moved from a first position characterized by a channel of the sealing element 164 being offset from and preventing flow between inlets and outlets of interconnected syringes and a second position characterized by the channel of the sealing element 164 being provided in axial alignment with the syringe outlets and inlets.
As shown in
Systems, devices and methods of the present disclosure are not limited to any particular therapeutic agent(s), solution(s), suspension(s), gas(es), or a combination thereof. Various embodiments comprise features and sealing elements for preventing materials in at least one syringe from escaping or migrating to another syringe. In some embodiments, for example, it is contemplated that that one or more non-lyophilized materials are provided in syringes of the present disclosure. In some embodiments, a gas (e.g. Nitrogen or Argon gas) is provided in a syringe for mixing with contents of a second syringe. Gas may be desirable, for example, to be provided with an active pharmaceutical ingredient to preserve that ingredient during storage. Sealing elements of the present disclosure are operable to and suitable for maintaining gas in a syringe and preventing unwanted migration of that gas. Sealing elements are also suitable and operable for preventing escape or flow of liquids and solids.
In some embodiments, mixing syringe systems of the present disclosure comprise gas-impermeable materials to prevent gas permeation and migration. However, in certain preferred embodiments, a first syringe 152 is initially provided with a liquid formulation component (i.e. liquid or flowable material) such as a polymer-solvent system and a second syringe is provided with an API, which may, in some non-limiting instances, be present as a lyophilized power. In such embodiments, the contents are stored separately with each respective syringe, which are interconnected to the syringe coupler with the displaceable member provided in the first position (
As disclosed herein, the syringe mixing system of the invention may comprise methods and systems for mixing components of a pharmaceutical composition or formulation comprising an API useful in the treatment in a disease or disorder in a patient. In some embodiments, the syringe mixing system comprises a first syringe containing a first gas, liquid, or solid composition and a second syringe containing a second gas, liquid, or solid composition. Upon activation of the syringe connector from a first, closed position to a second, open position, the first gas, liquid, or solid composition of the first syringe may be intermixed with the second gas, liquid, or solid composition of the second syringe (or vice versa) until a desired intermixed composition is formed. In some instances, the first or second syringe (but not both) may contain a gas component which may be an inert or volatile gas or gas vapor. In some instances, the first and second syringe may contain an aqueous based or organic based liquid which forms a solution, suspension, or both. In some further instances of the disclosed invention, the first syringe may comprise liquid formulation component or a solvent system which may, in some non-limiting examples, contain a biodegradable polymer dissolved or suspended within an aqueous, organic, or intermixed aqueous-organic solvent system, which may further contain additional co-solvents. In some instances, the first or second syringe (but not both) may contain a solid which may be an API useful in the treatment of a disease or disorder or amelioration of a symptom thereof. In some further instances, the solid may be a lyophilized powder, semi-solid particulate(s), or solid particulate(s) of varying sizes, shapes, and characteristics (e.g. specific surface area for example). Yet, further still, in some other non-limiting instances, the first or second syringe of the syringe device system may comprise a lyophilized powder, semi-solid particulate(s), or solid particulate(s) of varying sizes, shapes, and characteristics (e.g. specific surface area for example) which may be prepared and/or stored within the first or second syringe within the presence of a gas of choice, i.e. both lyophilized powder and gas are contained within the first or second syringe prior to mixing said components with the components stored within the opposing syringe, which may be, but is not necessarily limited to, a liquid of interest.
As disclosed herein, the syringe mixing system of the invention may comprise methods and systems for mixing components of a pharmaceutical composition or formulation comprising an API useful in the treatment of a disease or condition in a patient. Such a syringe mixing system may be referred to as a “prefilled syringe mixing system”, wherein the syringes of the syringe mixing system are prefilled with components of a pharmaceutical composition or formulation that are then mixed together using the syringe mixing system as described herein, such that the mixed pharmaceutical composition or formulation can then be administered to a patient in need of such pharmaceutical composition or formulation. In some embodiments of the invention, the syringe mixing device (prefilled syringe mixing system) may comprise a pharmaceutical formulation comprising: (a) an API, which is contained within the first syringe, and (b) a biodegradable polymer-solvent system contained within the second syringe, which may be intermixed upon activation of the syringe connector by a user such as to prepare a medication or medicament useful in the treatment of a disease or condition by administration of the mixed formulation into a patient in need thereof. The syringe mixing system can be used to store and then mix for administration any pharmaceutical composition or formulation that would benefit from the advantages of the inventive syringe mixing system, and the disease or condition to be treated will naturally depend on the drug or therapeutic agent included in the pharmaceutical composition or formulation.
In some embodiments, the API is a Gonadotrophin Releasing Hormone (GnRH) agonist or antagonist or a pharmaceutically acceptable salt thereof. Diseases or conditions that may be treated with a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof may include, but are not limited to, certain types of cancers, central precocious puberty (CPP), endometriosis, or uterine fibroids. In some instances, a cancer that may be treated with a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof may include but is not limited to prostate cancer (including but not limited to advanced prostate cancer) or breast cancer.
Leuprolide, as known as leuprorelin, is a synthetic peptide analog that acts as a “super agonist” upon pituitary GnRH receptors. GnRH agonists, such as leuprolide or a pharmaceutically acceptable salt thereof (such as leuprolide acetate), may be used in the treatment of prostate cancer (including advanced prostate cancer) in adult males, HR-positive breast cancer (including, but not limited, to HR-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer) and CPP. Administration of GnRH agonists (or GnRH) leads to downregulation of GnRH receptor activity, which in turn downregulates GnRH-dependent secretion of gonadotropins, including but not limited to, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Downregulation of LH and FSH leads to subsequent down-regulation of secondary sex-hormones, including but not limited to, testosterone and estradiol. Testosterone is a key metabolite in driving prostate cancer development and progression in adult males. As such, the reduction of serum testosterone levels is a useful clinical approach for slowing or inhibiting the growth of prostate cancer. Likewise, clinical approaches that modulate hormone activity and/or synthesis, particularly that of estrogens (e.g. estradiol), are useful for slowing or inhibiting the growth of hormone receptor-positive (HR-positive) breast cancer. Controlled release formulations for the extended release of leuprolide useful in the treatment of the prostate cancer in adult males, breast cancer, and CPP in pediatric patients 2 years old or older have been developed. Controlled release formulations using flowable biodegradable polymer based compositions for sustained, extended release of leuprolide or pharmaceutically acceptable salts thereof have been described, by way of example, in U.S. Pat. Nos. 6,565,874 and 8,470,359, WO 2020/2404170, and WO 2020/217170, each of which are incorporated herein by reference in their entireties.
As disclosed herein, the syringe device or mixing system may be used to subcutaneously administer an API to a patient in need thereof. In some embodiments, the API is a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof and the patient may suffer from prostate cancer, hormone receptor-positive breast cancer, or CPP. In some embodiments, the method of administering the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof comprises mixing a unit dose of the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof with a liquid formulation component to form a reconstituted pharmaceutical composition using the syringe-to-syringe mixing system; and administering the reconstituted pharmaceutical composition to the patient via subcutaneous injection. In some embodiments, the syringe-to-syringe mixing system comprises a first syringe barrel comprising the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof, a second syringe barrel comprising the liquid formulation component, and a syringe coupler comprising a displaceable member, wherein the displaceable member comprises a seal with a flow port that is offset from an outlet of at least one of the first syringe barrel and the second syringe barrel when the displaceable member is provided in a first position, and wherein the flow port is aligned with the outlet of the first syringe barrel and the second syringe barrel when the displaceable member is provided in a second position, and wherein the displaceable member is displaceable in a direction that is substantially perpendicular to a longitudinal axis of at least one of the first syringe barrel and the second syringe barrel. The mixing comprises applying a force to a user-interface to move the displaceable seal from the first position to the second position and applying force to a plunger positioned in the first syringe barrel and a plunger positioned in the second syringe barrel in an alternating manner to mix the contents of the first syringe barrel and the second syringe barrel. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate.
In one embodiment, a syringe device system comprises a composition, which when formulated according to the methods of using the syringe device system as described herein to intermix two separated components of the composition prior to administration, may be useful in the palliative treatment of prostate cancer, including the palliative treatment of advanced prostate cancer in an adult male patient, when administered by subcutaneous injection about once every month (once per month) to reduce the patient's serum testosterone level to less than or equal to 0.5 ng/mL. According to this embodiment, the syringe device system comprises a first syringe containing an amount of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof. In some instances, the syringe device system comprises a first syringe containing an amount of lyophilized leuprolide or a pharmaceutically acceptable salt thereof, such as lyophilized leuprolide acetate. In some instances, the amount of leuprolide or a pharmaceutically acceptable salt thereof in the delivered reconstituted product may be about 7.0 mg leuprolide free base equivalent. In some instances, the amount of leuprolide acetate in the delivered reconstituted product may be about 7.5 mg. As used herein, the term “free base equivalent” may refer to the conjugate base or deprotonated form of an amine containing compound or substance. For instance, about 7.0 mg of leuprolide represents the free base equivalent of about 7.5 mg of leuprolide acetate. According to this embodiment, the syringe device system comprises a second syringe containing an amount of a polymer-solvent system comprising an amount of a biodegradable polymer, which in some instances is a poly(D,L-lactide-co-glycolide) acid-initiated (i.e. PLGH) polymer, dissolved in a biocompatible solvent, which in some instances is NMP. In some instances, the biodegradable PLGH polymer may comprise a lactide to glycolide ratio of about 50:50. In some instances, the PLGH polymer may compromise a copolymer containing at least one carboxyl end group. In some instances, the PLGH polymer has a weight average molecular weight from about 31 kDa to about 45 kDa. In some instances, the amount of PLGH polymer in the delivered reconstituted product may be about 82.5 mg. In some instances, the amount of NMP in the delivered reconstituted product is about 160 mg. The term “weight average molecular weight,” unless otherwise specified, means a weight average molecular weight as measured by a conventional gel permeation chromatography (GPC) instrument (such as an Agilent 1260 Infinity Quaternary LC with Agilent G1362A Refractive Index Detector) utilizing polystyrene standards and tetrahydrofuran (THF) as the solvent.
According to the methods of activating the syringe device system, as disclosed herein, the user, after first allowing the pre-assembled syringe device system to equilibrate to room temperature and then removing it from its packaging, applies force to the user-interface portions 52 and 57 of the displaceable member 50 and the guide member 56, respectively, to activate the syringe coupler from the first closed position to the second open position. The user then applies a force to the second plunger disposed slidably within the second syringe to transfer the polymer-solvent system housed within the internal chamber of the second syringe barrel through the open, activated syringe coupler and into the internal chamber of the first syringe housing the lyophilized leuprolide acetate. Upon contact of the polymer-solvent system with the lyophilized leuprolide acetate, the leuprolide acetate will largely remain in suspension, thus requiring mixing with the polymer-solvent system to ensure that a homogeneous suspension is formed prior to administration. The user then applies a force to the first plunger disposed slidably within the first syringe to transfer the partially to fully mixed components back through the open syringe coupler and into the second syringe. The user will continue mixing the contents back and forth from the first and second syringes for between about 15 seconds and two minutes. In some instances, mixing is contemplated as continuing for about 25 seconds, about 45 seconds, or about 1 minute, equivalent to approximately 30-90 full back-and-forth cycles (and in some preferred embodiments, about 60 full back-and-forth cycles) to ensure that the lyophilized leuprolide acetate is fully suspended within the polymer-solvent system. The fully formulated composition is subsequently displaced into the second syringe at a final injection volume of about 0.25 mL and administered formulation weight of about 250 mg. The user then disconnects the second syringe containing the therapeutic formulation from the syringe device by de-threading attachment to the male extension 54 upon the displaceable member 50 of the syringe connector. The user then attaches a needle, for example an 18G to 20G needle, to the distal dispensing outlet of the second syringe. The user then subcutaneously administers the full formulation dose to an adult male prostate cancer patient in need of treatment thereof.
According to the methods of administering the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof to a patient with prostate cancer using the syringe device system disclosed herein, the method comprises subcutaneously administering at least one injection of a pharmaceutic composition comprising a unit dose of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof, once every month (once per month), to the patient to suppress the patient's serum testosterone level to less than or equal to 0.5 ng/ml. Prior to the administering, the pharmaceutic composition is reconstituted using the syringe device system comprising a first syringe barrel comprising the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof and a second syringe barrel comprising a liquid formulation component, the first and second syringe barrels being interconnected via a syringe coupler comprising a displaceable seal, wherein the displaceable seal being operable to be axially displaced from a first position to a second position by a force applied to a plunger of the first syringe barrel, and wherein the first position comprises a position in which material transfer through the syringe coupler is occluded, and the second position comprises a position in which at least a portion of the displaceable seal is not secured to an interior surface of the syringe coupler and material transfer through the syringe coupler is permitted. The pharmaceutic composition is reconstituted by applying a force to a user-interface to move the displaceable seal from the first position to the second position and applying force to a plunger positioned in the first syringe barrel and a plunger positioned in the second syringe barrel in an alternating manner to mix contents of the first syringe barrel and the second syringe barrel. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the pharmaceutical composition comprises about 7.5 mg of leuprolide acetate and N-methyl-2-pyrrolidone and a 50:50 poly(lactic acid-co-glycolic acid) (PLGA) copolymer having a weight average molecular weight from about 31 kDa to about 45 kDa and at least one terminal carboxylic acid end group as the liquid formulation component.
In another embodiment, a syringe device system comprises a composition, which when formulated according to the methods of using the syringe device system as described herein to intermix two separated components of the composition prior to administration, may be useful in the palliative treatment of prostate cancer, including the palliative treatment of advanced prostate cancer in an adult male patient, when administered by subcutaneous injection about once every three months (once per three months) to reduce the patient's serum testosterone level to less than or equal to 0.5 ng/mL. According to this embodiment, the syringe device system comprises a first syringe containing an amount of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof. In some instances, the syringe device system comprises a first syringe containing an amount of lyophilized leuprolide or a pharmaceutically acceptable salt thereof, such as lyophilized leuprolide acetate. In some instances, the amount of leuprolide or a pharmaceutically acceptable salt thereof in the delivered reconstituted product may be about 21.0 mg leuprolide free base equivalent. In some instances, the amount of leuprolide acetate in the delivered reconstituted product may be about 22.5 mg. According to this embodiment, the syringe device system comprises a second syringe containing an amount of a polymer-solvent system comprising an amount of a biodegradable polymer, which in some instances is a poly(D,L-lactide-co-glycolide) (i.e. PLG) polymer dissolved in a biocompatible solvent, which in some instances is NMP. In some instances, the biodegradable PLG polymer may comprise a lactide to glycolide ratio of about 75:25. In some instances, the PLG polymer may be initiated with hexanediol. In some instances, the PLG polymer may compromise a copolymer containing two primary hydroxyl end groups. In some instances, the PLG polymer has a weight average molecular weight range of about 17 kDa to about 21 kDa. In some instances, the amount of PLG polymer in the delivered reconstituted product may be about 158.6 mg. In some instances, the amount of NMP in the delivered reconstituted product is about 193.9 mg.
According to the methods of activating the syringe device system, as disclosed herein, the user, after first allowing the pre-assembled syringe device system to equilibrate to room temperature and then removing it from its packaging, applies force to the user-interface portions 52 and 57 of the displaceable member 50 and the guide member 56, respectively, to activate the syringe coupler from the first closed position to the second open position. The user then applies a force to the second plunger disposed slidably within the second syringe to transfer the polymer-solvent system housed within the internal chamber of the second syringe barrel through the open, activated syringe coupler and into the internal chamber of the first syringe housing the lyophilized leuprolide acetate. Upon contact of the polymer-solvent system with the lyophilized leuprolide acetate, the leuprolide acetate will largely remain in suspension, thus requiring mixing with the polymer-solvent system to ensure that a homogeneous suspension is formed prior to administration. The user then applies a force to the first plunger disposed slidably within the first syringe to transfer the partially to fully mixed components back through the open syringe coupler and into the second syringe. The user will continue mixing the contents back and forth from the first and second syringes, in some instances for about 1 minute, equivalent to approximately 60 full back-and-forth cycles to ensure that the lyophilized leuprolide acetate is fully suspended within the polymer-solvent system. The fully formulated composition is subsequently displaced into the second syringe at a final injection volume of about 0.375 mL and administered formulation weight of about 375 mg. The user then disconnects the second syringe containing the therapeutic formulation from the syringe device by de-threading attachment to the male extension 54 upon the displaceable member 50 of the syringe connector. The user then attaches a needle, for example an 18G to 20G needle, to the distal dispensing outlet of the second syringe. The user then subcutaneously administers the formulation dose to an adult male prostate cancer patient in need of treatment thereof.
According to the methods of administering the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof to a patient with prostate cancer using the syringe device system disclosed herein, the method comprises subcutaneously administering at least one injection of a pharmaceutic composition comprising a unit dose of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof, once every three months (once per three months), to the patient to suppress the patient's serum testosterone level to less than or equal to 0.5 ng/ml. Prior to the administering, the pharmaceutic composition is reconstituted using the syringe device system comprising a first syringe barrel comprising the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof and a second syringe barrel comprising a liquid formulation component, the first and second syringe barrels being interconnected via a syringe coupler comprising a displaceable seal, wherein the displaceable seal being operable to be axially displaced from a first position to a second position by a force applied to a plunger of the first syringe barrel, and wherein the first position comprises a position in which material transfer through the syringe coupler is occluded, and the second position comprises a position in which at least a portion of the displaceable seal is not secured to an interior surface of the syringe coupler and material transfer through the syringe coupler is permitted. The pharmaceutic composition is reconstituted by applying a force to a user-interface to move the displaceable seal from the first position to the second position and applying force to a plunger positioned in the first syringe barrel and a plunger positioned in the second syringe barrel in an alternating manner to mix contents of the first syringe barrel and the second syringe barrel. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the pharmaceutical composition comprises about 22.5 mg of leuprolide acetate and N-methyl-2-pyrrolidone, and a 75:25 poly(lactide-co-glycolide) (PLG) copolymer having a weight average molecular weight from about 17 kDa to about 21 kDa and end groups that are hydroxyl-terminated as the liquid formulation component.
In yet another embodiment, a syringe device system comprises a composition, which when formulated according to the methods of using the syringe device system as described herein to intermix two separated components of the composition prior to administration, may be useful in the palliative treatment of prostate cancer, including the palliative treatment of advanced prostate cancer in an adult male patient, when administered by subcutaneous injection about once every four months (once per four months) to reduce the patient's serum testosterone level to less than or equal to 0.5 ng/mL. According to this embodiment, the syringe device system comprises a first syringe containing an amount of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof. In some instances, the syringe device system comprises a first syringe containing an amount of lyophilized leuprolide or a pharmaceutically acceptable salt thereof, such as lyophilized leuprolide acetate. In some instances, the amount of leuprolide or a pharmaceutically acceptable salt thereof in the delivered reconstituted product may be about 28.0 mg leuprolide free base equivalent. In some instances, the amount of leuprolide acetate in the delivered reconstituted product may be about 30.0 mg. According to this embodiment, the syringe device system comprises a second syringe containing an amount of a polymer-solvent system comprising an amount of a biodegradable polymer, which in some instances is a poly(D,L-lactide-co-glycolide) (i.e. PLG) polymer formulation dissolved in a biocompatible solvent, which in some instances is NMP. In some instances, the biodegradable PLG polymer may comprise a lactide to glycolide ratio of about 75:25. In some instances, the PLG polymer may be initiated with hexanediol. In some instances, the PLG polymer may compromise a copolymer containing two primary hydroxyl end groups. In some instances, the PLG polymer has a weight average molecular weight range of about 17 kDa to about 21 kDa. In some instances, the amount of PLG polymer in the delivered reconstituted product may be about 211.5 mg. In some instances, the amount of NMP in the delivered reconstituted product is about 258.5 mg.
According to the methods of activating the syringe device system, as disclosed herein, the user, after first allowing the pre-assembled syringe device system to equilibrate to room temperature and then removing it from its packaging, applies force to the user-interface portions 52 and 57 of the displaceable member 50 and the guide member 56, respectively, to activate the syringe coupler from the first closed position to the second open position. The user then applies a force to the second plunger disposed slidably within the second syringe to transfer the polymer-solvent system housed within the internal chamber of the second syringe barrel through the open, activated syringe coupler and into the internal chamber of the first syringe housing the lyophilized leuprolide acetate. Upon contact of the polymer-solvent system with the lyophilized leuprolide acetate, the leuprolide acetate will largely remain in suspension, thus requiring mixing with the polymer-solvent system to ensure that a homogeneous suspension is formed prior to administration. The user then applies a force to the first plunger disposed slidably within the first syringe to transfer the partially to fully mixed components back through the open syringe coupler and into the second syringe. The user will continue mixing the contents back and forth from the first and second syringes, in some instances for about 1 minute, equivalent to approximately 60 full back-and-forth cycles to ensure that the lyophilized leuprolide acetate is fully suspended within the polymer-solvent system. The fully formulated composition is subsequently displaced into the second syringe at a final injection volume of about 0.5 mL and administered formulation weight of about 500 mg. The user then disconnects the second syringe containing the therapeutic formulation from the syringe device by de-threading attachment to the male extension 54 upon the displaceable member 50 of the syringe connector. The user then attaches a needle, for example an 18G to 20G needle, to the distal dispensing outlet of the second syringe. The user then subcutaneously administers the full formulation dose to an adult male prostate cancer patient in need of treatment thereof.
According to the methods of administering the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof to a patient with prostate cancer using the syringe device system disclosed herein, the method comprises subcutaneously administering at least one injection of a pharmaceutic composition comprising a unit dose of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof, once every four months (once per four months), to the patient to suppress the patient's serum testosterone level to less than or equal to 0.5 ng/ml. Prior to the administering, the pharmaceutic composition is reconstituted using the syringe device system comprising a first syringe barrel comprising the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof and a second syringe barrel comprising a liquid formulation component, the first and second syringe barrels being interconnected via a syringe coupler comprising a displaceable seal, wherein the displaceable seal being operable to be axially displaced from a first position to a second position by a force applied to a plunger of the first syringe barrel, and wherein the first position comprises a position in which material transfer through the syringe coupler is occluded, and the second position comprises a position in which at least a portion of the displaceable seal is not secured to an interior surface of the syringe coupler and material transfer through the syringe coupler is permitted. The pharmaceutic composition is reconstituted by applying a force to a user-interface to move the displaceable seal from the first position to the second position and applying force to a plunger positioned in the first syringe barrel and a plunger positioned in the second syringe barrel in an alternating manner to mix contents of the first syringe barrel and the second syringe barrel. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the pharmaceutical composition comprises about 30 mg of leuprolide acetate and N-methyl-2-pyrrolidone, and a 75:25 poly(lactide-co-glycolide) (PLG) copolymer having a weight average molecular weight from about 17 kDa to about 21 kDa and end groups that are hydroxyl-terminated as the liquid formulation component.
In yet another embodiment of the invention, the syringe device system comprises a composition, which when formulated according to the methods of using the syringe device system as described herein to intermix two separated components of the composition prior to administration, may be useful in the palliative treatment of prostate cancer, including the palliative treatment of advanced prostate cancer in an adult male patient, when administered by subcutaneous injection about once every six months (once per six months) to reduce the patient's serum testosterone level to less than or equal to 0.5 ng/mL. According to this embodiment, the syringe device system comprises a first syringe containing an amount of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof. In some instances, the syringe device system comprises a first syringe containing an amount of lyophilized leuprolide or a pharmaceutically acceptable salt thereof, such as lyophilized leuprolide acetate. In some instances, the amount of leuprolide or a pharmaceutically acceptable salt thereof in the delivered reconstituted product may be about 42.0 mg leuprolide free base equivalent. In some instances, the amount of leuprolide acetate in the delivered reconstituted product may be about 45.0 mg. According to this embodiment, the syringe device system comprises a second syringe containing an amount of a polymer-solvent system comprising an amount of a biodegradable polymer, which in some instances is a poly(D,L-lactide-co-glycolide) (i.e. PLG) polymer formulation dissolved in a biocompatible solvent, which in some instances is NMP. In some instances, the biodegradable PLG polymer may comprise a lactide to glycolide ratio of about 85:15. In some instances, the PLG polymer may be initiated with hexanediol. In some instances, the PLG polymer may compromise a copolymer containing two primary hydroxyl end groups. In some instances, the PLG polymer has a weight average molecular weight range of about 20 kDa to about 26 kDa. In some instances, the amount of PLG polymer in the delivered reconstituted product may be about 165 mg. In some instances, the amount of NMP in the delivered reconstituted product is about 165 mg.
According to the methods of activating the syringe device system, as disclosed herein, the user, after first allowing the pre-assembled syringe device system to equilibrate to room temperature and then removing it from its packaging, applies force to the user-interface portions 52 and 57 of the displaceable member 50 and the guide member 56, respectively, to activate the syringe coupler from the first closed position to the second open position. The user then applies a force to the second plunger disposed slidably within the second syringe to transfer the polymer-solvent system housed within the internal chamber of the second syringe barrel through the open, activated syringe coupler and into the internal chamber of the first syringe housing the lyophilized leuprolide acetate. Upon contact of the polymer-solvent system with the lyophilized leuprolide acetate, the leuprolide acetate will largely remain in suspension, thus requiring mixing with the polymer-solvent system to ensure that a homogeneous suspension is formed prior to administration. The user then applies a force to the first plunger disposed slidably within the first syringe to transfer the partially to fully mixed components back through the open syringe coupler and into the second syringe. The user will continue mixing the contents back and forth from the first and second syringes, in some instances for about 1 minute, equivalent to approximately 60 full back-and-forth cycles to ensure that the lyophilized leuprolide acetate is fully suspended within the polymer-solvent system. The fully formulated composition is subsequently displaced into the second syringe at a final injection volume of about 0.375 mL and administered formulation weight of about 375 mg. The user then disconnects the second syringe containing the therapeutic formulation from the syringe device by de-threading attachment to the male extension 54 upon the displaceable member 50 of the syringe connector. The user then attaches a needle, for example an 18G to 20G needle, to the distal dispensing outlet of the second syringe. The user then subcutaneously administers the full formulation dose to an adult male prostate cancer patient in need of treatment thereof.
According to the methods of administering the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof to a patient with prostate cancer using the syringe device system disclosed herein, the method comprises subcutaneously administering at least one injection of a pharmaceutic composition comprising a unit dose of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof, once every six months (once per six months), to the patient to suppress the patient's serum testosterone level to less than or equal to 0.5 ng/ml. Prior to the administering, the pharmaceutic composition is reconstituted using the syringe device system comprising a first syringe barrel comprising the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof and a second syringe barrel comprising a liquid formulation component, the first and second syringe barrels being interconnected via a syringe coupler comprising a displaceable seal, wherein the displaceable seal being operable to be axially displaced from a first position to a second position by a force applied to a plunger of the first syringe barrel, and wherein the first position comprises a position in which material transfer through the syringe coupler is occluded, and the second position comprises a position in which at least a portion of the displaceable seal is not secured to an interior surface of the syringe coupler and material transfer through the syringe coupler is permitted. The pharmaceutic composition is reconstituted by applying a force to a user-interface to move the displaceable seal from the first position to the second position and applying force to a plunger positioned in the first syringe barrel and a plunger positioned in the second syringe barrel in an alternating manner to mix contents of the first syringe barrel and the second syringe barrel. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the pharmaceutical composition comprises about 45 mg of leuprolide acetate and N-methyl-2-pyrrolidone, and an 85:15 poly(lactide-co-glycolide) (PLG) copolymer having a weight average molecular weight from about 20 kDa to about 26 kDa and end groups that are hydroxyl-terminated as the liquid formulation component.
In yet another embodiment, a syringe device system comprises a composition, which when formulated according to the methods of using the syringe device system as described herein to intermix two separated components of the composition prior to administration, may be useful in suppressing ovarian function in a patient with HR-positive breast cancer. The composition may further be useful in suppressing one or more of the patient's estradiol (E2) level to less than 20 pg/mL, the patient's follicle stimulating hormone (FSH) level to less than 40 IU/L, and patient's mean serum luteinizing hormone (LH) level. In some instances, the composition may be administered concurrently with one or more other therapeutic treatments for HR-positive breast cancer, including, but not limited to endocrine therapy, chemotherapy, and/or radiotherapy. In some instances, the composition is administered by subcutaneous injection about once every three months (once per three months). According to this embodiment, the syringe device system comprises a first syringe containing an amount of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof. In some instances, the syringe device system comprises a first syringe containing an amount of lyophilized leuprolide or a pharmaceutically acceptable salt thereof, such as lyophilized leuprolide acetate. In some instances, the amount of leuprolide or a pharmaceutically acceptable salt thereof in the delivered reconstituted product may be about 26 mg to about 30 mg, preferably 28 mg leuprolide free base equivalent. In some instances, the amount of leuprolide acetate in the delivered reconstituted product may be about 28 mg to about 32 mg, preferably 30 mg. According to this embodiment, the syringe device system comprises a second syringe containing an amount of a polymer-solvent system comprising an amount of a biodegradable polymer, which in some instances is a poly(D,L-lactide-co-glycolide) (i.e. PLG) polymer formulation dissolved in a biocompatible solvent, which in some instances is NMP. In some instances, the biodegradable PLG polymer may comprise a lactide to glycolide ratio of about 70:30 to about 80:20, preferably about 75:25. In some instances, the PLG polymer may be initiated with hexanediol. In some instances, the PLG polymer may compromise a copolymer containing two primary hydroxyl end groups. In some instances, the PLG polymer may be initiated with dodecanol. In some instances, the PLG polymer may compromise a copolymer containing a hydroxyl end group and an ester end group. In some instances, the PLG polymer has a weight average molecular weight range of about 15 kDa to about 45 kDa, preferably about 17 kDa to about 21 kDa. In some instances, the amount of PLG polymer in the delivered reconstituted product may be about 158.6 mg. In some instances, the amount of NMP in the delivered reconstituted product is about 193.9 mg.
According to the methods of activating the syringe device system, as disclosed herein, the user, after first allowing the pre-assembled syringe device system to equilibrate to room temperature and then removing it from its packaging, applies force to the user-interface portions 52 and 57 of the displaceable member 50 and the guide member 56, respectively, to activate the syringe coupler from the first closed position to the second open position. The user then applies a force to the second plunger disposed slidably within the second syringe to transfer the polymer-solvent system housed within the internal chamber of the second syringe barrel through the open, activated syringe coupler and into the internal chamber of the first syringe housing the lyophilized leuprolide acetate. Upon contact of the polymer-solvent system with the lyophilized leuprolide acetate, the leuprolide acetate will largely remain in suspension, thus requiring mixing with the polymer-solvent system to ensure that a homogeneous suspension is formed prior to administration. The user then applies a force to the first plunger disposed slidably within the first syringe to transfer the partially to fully mixed components back through the open syringe coupler and into the second syringe. The user will continue mixing the contents back and forth from the first and second syringes, in some instances for about 1 minute, equivalent to approximately 60 full back-and-forth cycles to ensure that the lyophilized leuprolide acetate is fully suspended within the polymer-solvent system. The fully formulated composition is subsequently displaced into the second syringe at a final injection volume of about 0.375 mL and administered formulation weight of about 375 mg to about 400 mg. The user then disconnects the second syringe containing the therapeutic formulation from the syringe device by de-threading attachment to the male extension 54 upon the displaceable member 50 of the syringe connector. The user then attaches a needle, for example a 18G to 20G needle, to the distal dispensing outlet of the second syringe. The user then subcutaneously administers the full formulation dose to an adult breast cancer patient in need of treatment thereof.
According to the methods of administering the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof to a patient with hormone receptor-positive breast cancer using the syringe device system disclosed herein, the method comprises subcutaneously administering at least one injection of a pharmaceutic composition comprising a unit dose of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof, once every three months (once per three months), to the patient to suppress the patient's ovarian function. In some instances, administering the at least one injection of the pharmaceutic composition comprising a unit dose of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof, once every three months, to the patient suppresses one or more of the patient's estradiol (E2) level to less than 20 pg/mL, the patient's follicle stimulating hormone (FSH) level to less than 40 IU/L, and patient's mean serum luteinizing hormone (LH) level. Prior to the administering, the pharmaceutic composition is reconstituted using the syringe device system comprising a first syringe barrel comprising the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof and a second syringe barrel comprising a liquid formulation component, the first and second syringe barrels being interconnected via a syringe coupler comprising a displaceable seal, wherein the displaceable seal being operable to be axially displaced from a first position to a second position by a force applied to a plunger of the first syringe barrel, and wherein the first position comprises a position in which material transfer through the syringe coupler is occluded, and the second position comprises a position in which at least a portion of the displaceable seal is not secured to an interior surface of the syringe coupler and material transfer through the syringe coupler is permitted. The pharmaceutic composition is reconstituted by applying a force to a user-interface to move the displaceable seal from the first position to the second position and applying force to a plunger positioned in the first syringe barrel and a plunger positioned in the second syringe barrel in an alternating manner to mix contents of the first syringe barrel and the second syringe barrel. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the pharmaceutical composition comprises about 30 mg of leuprolide acetate and N-methyl-2-pyrrolidone and a 75:25 poly(lactide-co-glycolide) (PLG) copolymer having a weight average molecular weight from about 17 kDa to about 21 kDa and one distal end group that is hydroxyl-terminated and the other distal end group that is either hydroxyl-terminated or ester-terminated as the liquid formulation component.
In yet another embodiment of the invention, the syringe device system comprises a composition, which when formulated according to the methods of using the syringe device system as described herein to intermix two separated components of the composition prior to administration, may be useful in the treatment of CPP in a pediatric patient 2 years of age or older, when administered by subcutaneous injection about once every six months (once per six months) to reduce the pediatric patient's peak stimulated blood serum LH concentration to a pre-pubertal concentration level of less than 4 IU/L. According to this embodiment, the syringe device system comprises a first syringe containing an amount of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof. In some instances, the syringe device system comprises a first syringe containing an amount of lyophilized leuprolide or a pharmaceutically acceptable salt thereof, such as lyophilized leuprolide acetate. In some instances, the amount of leuprolide or a pharmaceutically acceptable salt thereof in the delivered reconstituted product may be about 42.0 mg leuprolide free base equivalent. In some instances, the amount of leuprolide acetate in the delivered reconstituted product may be about 45.0 mg. According to this embodiment, the syringe device system comprises a second syringe containing an amount of a polymer-solvent system comprising an amount of a biodegradable polymer, which in some instances is a poly(D,L-lactide-co-glycolide) (i.e. PLG) polymer formulation dissolved in a biocompatible solvent, which in some instances is NMP. In some instances, the biodegradable PLG polymer may comprise a lactide to glycolide ratio of about 85:15. In some instances, the PLG polymer may be initiated with hexanediol. In some instances, the PLG polymer may compromise a copolymer containing two primary hydroxyl end groups. In some instances, the PLG polymer may be initiated with dodecanol. In some instances, the PLG polymer may compromise a copolymer containing a hydroxyl end group and an ester end group. In some instances, the PLG polymer has a weight average molecular weight range of about 20 kDa to about 26 kDa. In some instances, the amount of PLG polymer in the delivered reconstituted product may be about 165 mg. In some instances, the amount of NMP in the delivered reconstituted product is about 165 mg.
According to the methods of activating the syringe device system, as disclosed herein, the user, after first allowing the pre-assembled syringe device system to equilibrate to room temperature and then removing it from its packaging, applies force to the user-interface portions 52 and 57 of the displaceable member 50 and the guide member 56, respectively, to activate the syringe coupler from the first closed position to the second open position. The user then applies a force to the second plunger disposed slidably within the second syringe to transfer the polymer-solvent system housed within the internal chamber of the second syringe barrel through the open, activated syringe coupler and into the internal chamber of the first syringe housing the lyophilized leuprolide acetate. Upon contact of the polymer-solvent system with the lyophilized leuprolide acetate, the leuprolide acetate will largely remain in suspension, thus requiring mixing with the polymer-solvent system to ensure that a homogeneous suspension is formed prior to administration. The user then applies a force to the first plunger disposed slidably within the first syringe to transfer the partially to fully mixed components back through the open syringe coupler and into the second syringe. The user will continue mixing the contents back and forth from the first and second syringes, in some instances for about 1 minute, equivalent to approximately 60 full back-and-forth cycles to ensure that the lyophilized leuprolide acetate is fully suspended within the polymer-solvent system. The fully formulated composition is subsequently displaced into the second syringe at a final injection volume of about 0.375 mL and administered formulation weight of about 375 mg. The user then disconnects the second syringe containing the therapeutic formulation from the syringe device by de-threading attachment to the male extension 54 upon the displaceable member 50 of the syringe connector. The user then attaches a needle, for example an 18G to 20G needle, to the distal dispensing outlet of the second syringe. The user then subcutaneously administers the full formulation dose to a pediatric patient 2 years of age or older in need of treatment thereof.
According to the methods of administering the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof to a pediatric patient 2 years of age or older with central precocious puberty (CPP) using the syringe device system disclosed herein, the method comprises subcutaneously administering at least one injection of a pharmaceutic composition comprising a unit dose of a GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof, once every six months (once per six months), to the pediatric patient to reduce the pediatric patient's peak stimulated blood serum LH concentration to a pre-pubertal concentration of less than 4 IU/L. Prior to the administering, the pharmaceutic composition is reconstituted using the syringe device system comprising a first syringe barrel comprising the GnRH agonist or antagonist or a pharmaceutically acceptable salt thereof and a second syringe barrel comprising a liquid formulation component, the first and second syringe barrels being interconnected via a syringe coupler comprising a displaceable seal, wherein the displaceable seal being operable to be axially displaced from a first position to a second position by a force applied to a plunger of the first syringe barrel, and wherein the first position comprises a position in which material transfer through the syringe coupler is occluded, and the second position comprises a position in which at least a portion of the displaceable seal is not secured to an interior surface of the syringe coupler and material transfer through the syringe coupler is permitted. The pharmaceutic composition is reconstituted by applying a force to a user-interface to move the displaceable seal from the first position to the second position and applying force to a plunger positioned in the first syringe barrel and a plunger positioned in the second syringe barrel in an alternating manner to mix contents of the first syringe barrel and the second syringe barrel. In some instances, the GnRH agonist or antagonist or the pharmaceutically acceptable salt thereof is leuprolide or a pharmaceutically acceptable salt thereof, such as leuprolide acetate. In some instances, the pharmaceutical composition comprises about 45 mg of leuprolide acetate and N-methyl-2-pyrrolidone and an 85:15 poly(lactide-co-glycolide) (PLG) copolymer having a weight average molecular weight from about 20 kDa to about 26 kDa and one distal end group that is hydroxyl-terminated and the other distal end group that is either hydroxyl-terminated or ester-terminated as the liquid formulation component.
Various features and embodiments of a pre-connected syringe-to-syringe device and system and methods of using the pre-connected syringe-to-syringe device have been provided herein. It will be recognized, however, that various features are not necessarily specific to certain embodiments and may be provided on any one or more embodiments. The present disclosure and embodiments provided herein are not mutually exclusive and may be combined, substituted, and omitted. The scope of the invention(s) provided herein is thus not limited to any particular embodiment, drawing, or particular arrangement of features.
While various embodiments of the present disclosure have been described in detail, it is apparent that modifications and alterations of those embodiments will occur to those skilled in the art. However, it is to be expressly understood that such modifications and alterations are within the scope and spirit of the present disclosure. Further, the invention(s) described herein are capable of other embodiments and of being practiced or of being carried out in various ways. In addition, it is to be understood that the phraseology and terminology used herein is for the purposes of description and should not be regarded as limiting. The use of “including,” “comprising,” or “adding” and variations thereof herein are meant to encompass the items listed thereafter and equivalents thereof, as well as, additional items.
This U.S. Non-Provisional Patent Application is a Continuation of and claims the benefit of priority of International Application PCT/IB2021/062218, filed Dec. 22, 2021, and claims the benefit of priority of U.S. Provisional Patent Application Ser. No. 63/130,144, filed on Dec. 23, 2020, the entire disclosures of which are hereby incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4464174 | Ennis | Aug 1984 | A |
| 4543094 | Barnwell | Sep 1985 | A |
| 4549554 | Markham | Oct 1985 | A |
| 5286257 | Fischer | Feb 1994 | A |
| 5445614 | Haber et al. | Aug 1995 | A |
| 5674195 | Truthan | Oct 1997 | A |
| 6349850 | Cheikh | Feb 2002 | B1 |
| 6565874 | Dunn et al. | May 2003 | B1 |
| 6602223 | Szapiro | Aug 2003 | B2 |
| 6685922 | Peterson | Feb 2004 | B2 |
| 6729370 | Norton et al. | May 2004 | B2 |
| 6779566 | Engel | Aug 2004 | B2 |
| 6817987 | Vetter et al. | Nov 2004 | B2 |
| 7081109 | Tighe et al. | Jul 2006 | B2 |
| 7128105 | Tribble et al. | Oct 2006 | B2 |
| 7670326 | Shemesh | Mar 2010 | B2 |
| 7731065 | Ingram et al. | Jun 2010 | B2 |
| 7776011 | Tennican et al. | Aug 2010 | B2 |
| 7789862 | Thorne, Jr. | Sep 2010 | B2 |
| 7951108 | Harper et al. | May 2011 | B2 |
| 8002737 | Tennican | Aug 2011 | B2 |
| 8100853 | Glynn | Jan 2012 | B2 |
| 8337557 | Collins et al. | Dec 2012 | B2 |
| 8470359 | Dunn | Jun 2013 | B2 |
| 8834449 | Machan et al. | Sep 2014 | B2 |
| 9016925 | Faccioli et al. | Apr 2015 | B2 |
| 9220577 | Jessop et al. | Dec 2015 | B2 |
| 9289562 | Thorne, Jr. et al. | Mar 2016 | B2 |
| 9522098 | Tuckwell et al. | Dec 2016 | B2 |
| 9586008 | Shetty et al. | Mar 2017 | B2 |
| 9592343 | Shetty et al. | Mar 2017 | B2 |
| 9597454 | Wetzel et al. | Mar 2017 | B2 |
| 9833558 | Anderson et al. | Dec 2017 | B2 |
| 9872962 | Granelli | Jan 2018 | B2 |
| 9873098 | Asada et al. | Jan 2018 | B2 |
| 9962492 | Anderson et al. | May 2018 | B2 |
| 10046154 | Fangrow et al. | Aug 2018 | B2 |
| 10080882 | Ekman et al. | Sep 2018 | B2 |
| 10194964 | Schlachter et al. | Feb 2019 | B2 |
| 10278897 | David et al. | May 2019 | B2 |
| 10285907 | David et al. | May 2019 | B2 |
| 10322235 | Thorne, Jr. et al. | Jun 2019 | B2 |
| D863546 | Converse et al. | Oct 2019 | S |
| 10485930 | Tennican et al. | Nov 2019 | B2 |
| 10524983 | Tennican | Jan 2020 | B2 |
| 10653837 | Larsen | May 2020 | B2 |
| 10669063 | Stratis et al. | Jun 2020 | B2 |
| 10703532 | Stratis et al. | Jul 2020 | B2 |
| 10864139 | Genosar | Dec 2020 | B2 |
| 10898651 | Wetzel et al. | Jan 2021 | B2 |
| 10918796 | Larsen et al. | Feb 2021 | B2 |
| D948034 | Converse et al. | Apr 2022 | S |
| 20010037091 | Wironen et al. | Nov 2001 | A1 |
| 20030180262 | Wironen et al. | Sep 2003 | A1 |
| 20030225378 | Wilkie | Dec 2003 | A1 |
| 20070255204 | McLean et al. | Nov 2007 | A1 |
| 20080124397 | Wironen et al. | May 2008 | A1 |
| 20080150281 | Rome et al. | Jun 2008 | A1 |
| 20080167621 | Wagner et al. | Jul 2008 | A1 |
| 20100030111 | Perriere | Feb 2010 | A1 |
| 20100121271 | Perriere | May 2010 | A1 |
| 20130018326 | Hooven et al. | Jan 2013 | A1 |
| 20130178823 | Buchine et al. | Jul 2013 | A1 |
| 20130274656 | Dehan et al. | Oct 2013 | A1 |
| 20140195704 | Bhatia et al. | Jul 2014 | A1 |
| 20140251438 | Gettings et al. | Sep 2014 | A1 |
| 20140261082 | Anderson | Sep 2014 | A1 |
| 20140276385 | Buchine et al. | Sep 2014 | A1 |
| 20140323970 | Duncan | Oct 2014 | A1 |
| 20150174336 | Buchine et al. | Jun 2015 | A1 |
| 20150204451 | Wattellier et al. | Jul 2015 | A1 |
| 20150217058 | Hooven et al. | Aug 2015 | A1 |
| 20150219099 | Wattellier et al. | Aug 2015 | A1 |
| 20150231334 | Buchine et al. | Aug 2015 | A1 |
| 20150367072 | Constantineau et al. | Dec 2015 | A1 |
| 20150367073 | Standley et al. | Dec 2015 | A1 |
| 20150374917 | Standley et al. | Dec 2015 | A1 |
| 20150374925 | Standley et al. | Dec 2015 | A1 |
| 20160120527 | Larsen et al. | May 2016 | A1 |
| 20160144105 | Hooven et al. | May 2016 | A1 |
| 20160160854 | Dehan et al. | Jun 2016 | A1 |
| 20160195074 | Beard et al. | Jul 2016 | A1 |
| 20160220764 | Durvasula et al. | Aug 2016 | A1 |
| 20160243060 | Standley et al. | Aug 2016 | A1 |
| 20160263320 | Constantineau et al. | Sep 2016 | A1 |
| 20160331682 | Payet-Burin | Nov 2016 | A1 |
| 20170100541 | Constantineau et al. | Apr 2017 | A1 |
| 20170135903 | Wattelier et al. | May 2017 | A1 |
| 20170144118 | Gettings | May 2017 | A1 |
| 20170189619 | Constantineau et al. | Jul 2017 | A1 |
| 20170196771 | Hooven et al. | Jul 2017 | A1 |
| 20170209642 | Hooven et al. | Jul 2017 | A1 |
| 20170232196 | Constantineau et al. | Aug 2017 | A1 |
| 20170232197 | Standley et al. | Aug 2017 | A1 |
| 20170259007 | Standley et al. | Sep 2017 | A1 |
| 20180043107 | Hooven et al. | Feb 2018 | A1 |
| 20180099095 | Standley et al. | Apr 2018 | A1 |
| 20180110922 | Dunki-Jacobs et al. | Apr 2018 | A1 |
| 20180110928 | Constantineau et al. | Apr 2018 | A1 |
| 20180110931 | Standley et al. | Apr 2018 | A1 |
| 20180126076 | Constantineau et al. | May 2018 | A1 |
| 20180140774 | Constantineau et al. | May 2018 | A1 |
| 20180161497 | Hooven et al. | Jun 2018 | A1 |
| 20180161501 | Standley et al. | Jun 2018 | A1 |
| 20180207369 | Converse et al. | Jul 2018 | A1 |
| 20180221574 | Dunki-Jacobs et al. | Aug 2018 | A1 |
| 20190167910 | Buchine et al. | Jun 2019 | A1 |
| 20190240407 | Constantineau et al. | Aug 2019 | A1 |
| 20190275250 | Constantineau et al. | Sep 2019 | A1 |
| 20190350592 | Bagaoisan et al. | Nov 2019 | A1 |
| 20190374726 | Durvasula et al. | Dec 2019 | A1 |
| 20200061292 | Dunki-Jacobs et al. | Feb 2020 | A1 |
| 20200139048 | Buchine et al. | May 2020 | A1 |
| 20200146938 | Bourelle et al. | May 2020 | A1 |
| 20200147314 | Howlett et al. | May 2020 | A1 |
| 20200214625 | Hooven et al. | Jul 2020 | A1 |
| 20200316290 | Bourelle et al. | Oct 2020 | A1 |
| 20200338257 | Hooven et al. | Oct 2020 | A1 |
| 20200338258 | Standley et al. | Oct 2020 | A1 |
| 20210145697 | Bourelle et al. | May 2021 | A1 |
| 20210186813 | Bourelle et al. | Jun 2021 | A1 |
| 20210260282 | Dunki-Jacobs et al. | Aug 2021 | A1 |
| 20210268178 | Hooven et al. | Sep 2021 | A1 |
| 20210338928 | Hooven et al. | Nov 2021 | A1 |
| 20210353222 | Hooven et al. | Nov 2021 | A1 |
| 20210386621 | Hooven et al. | Dec 2021 | A1 |
| 20220001112 | Chagnon et al. | Jan 2022 | A1 |
| 20220184312 | Wattellier et al. | Jun 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2014007377 | Jun 2012 | AP |
| 489991 | Dec 2010 | AT |
| 2007324478 | May 2008 | AU |
| 2008219304 | Aug 2008 | AU |
| 2011346979 | Jul 2013 | AU |
| 2013294886 | Jan 2015 | AU |
| 2014232211 | Oct 2015 | AU |
| 2014281715 | Jan 2016 | AU |
| 2014294854 | Feb 2016 | AU |
| 2014294901 | Feb 2016 | AU |
| 2014294902 | Feb 2016 | AU |
| 2014364433 | Aug 2016 | AU |
| 2015212986 | Aug 2016 | AU |
| 2015305635 | Apr 2017 | AU |
| 2015305636 | Apr 2017 | AU |
| 2015305638 | Apr 2017 | AU |
| 2015305641 | Apr 2017 | AU |
| 2015364280 | Jul 2017 | AU |
| 2017014274 | Aug 2017 | AU |
| 2017014275 | Aug 2017 | AU |
| 2016235138 | Oct 2017 | AU |
| 2016266657 | Nov 2017 | AU |
| 2016296096 | Jan 2018 | AU |
| 2016306797 | Feb 2018 | AU |
| 2018200957 | Aug 2018 | AU |
| 2018278883 | Jan 2019 | AU |
| 2019200849 | Feb 2019 | AU |
| 2019203236 | May 2019 | AU |
| 2018230507 | Oct 2019 | AU |
| 2018271998 | Dec 2019 | AU |
| 2018285530 | Jan 2020 | AU |
| 2018347573 | Apr 2020 | AU |
| 2018352580 | Apr 2020 | AU |
| 2020202709 | May 2020 | AU |
| 2021200878 | Mar 2021 | AU |
| 2019364364 | May 2021 | AU |
| 2019419507 | Aug 2021 | AU |
| 2020316106 | Feb 2022 | AU |
| 2022200891 | Mar 2022 | AU |
| PI0719149 | Feb 2014 | BR |
| PI0807713 | Jun 2014 | BR |
| 112015001330 | Jul 2017 | BR |
| 112013015995 | Jul 2018 | BR |
| 112020007113 | Sep 2020 | BR |
| 112020007429 | Oct 2020 | BR |
| 112021012996 | Sep 2021 | BR |
| 2670206 | May 2008 | CA |
| 2822406 | Jun 2008 | CA |
| 2678523 | Aug 2008 | CA |
| 2843227 | Dec 2012 | CA |
| 2876056 | Jan 2014 | CA |
| 2905207 | Sep 2014 | CA |
| 2918927 | Jan 2015 | CA |
| 2918995 | Jan 2015 | CA |
| 2919004 | Jan 2015 | CA |
| 2934538 | Jun 2015 | CA |
| 2936721 | Jul 2015 | CA |
| 2938059 | Aug 2015 | CA |
| 2994801 | Feb 2016 | CA |
| 2994802 | Feb 2016 | CA |
| 2994803 | Feb 2016 | CA |
| 2994804 | Feb 2016 | CA |
| 2971440 | Jun 2016 | CA |
| 3032681 | Jun 2016 | CA |
| 2980585 | Sep 2016 | CA |
| 3019104 | Dec 2016 | CA |
| 2991441 | Jan 2017 | CA |
| 2994300 | Feb 2017 | CA |
| 2994386 | Aug 2018 | CA |
| 3055922 | Sep 2018 | CA |
| 175996 | Nov 2018 | CA |
| 183851 | Nov 2018 | CA |
| 3064324 | Nov 2018 | CA |
| 3066471 | Dec 2018 | CA |
| 3078633 | Apr 2019 | CA |
| 3078964 | Apr 2019 | CA |
| 3077095 | May 2019 | CA |
| 3117324 | Apr 2020 | CA |
| 3125287 | Jul 2020 | CA |
| 3146856 | Jan 2021 | CA |
| 101553266 | Oct 2009 | CN |
| 101616709 | Dec 2009 | CN |
| 103402619 | Nov 2013 | CN |
| 104379977 | Feb 2015 | CN |
| 105407943 | Mar 2016 | CN |
| 105531476 | Apr 2016 | CN |
| 105556119 | May 2016 | CN |
| 105612346 | May 2016 | CN |
| 106061253 | Oct 2016 | CN |
| 106132379 | Nov 2016 | CN |
| 106163501 | Nov 2016 | CN |
| 106573111 | Apr 2017 | CN |
| 106794305 | May 2017 | CN |
| 107073201 | Aug 2017 | CN |
| 107106771 | Aug 2017 | CN |
| 107205938 | Sep 2017 | CN |
| 107580489 | Jan 2018 | CN |
| 107921208 | Apr 2018 | CN |
| 108289998 | Jul 2018 | CN |
| 108290000 | Jul 2018 | CN |
| 108404261 | Aug 2018 | CN |
| 110464917 | Nov 2019 | CN |
| 110996876 | Apr 2020 | CN |
| 111132710 | May 2020 | CN |
| 111344064 | Jun 2020 | CN |
| 111601578 | Aug 2020 | CN |
| 111629703 | Sep 2020 | CN |
| 111655313 | Sep 2020 | CN |
| 111803762 | Oct 2020 | CN |
| 112245287 | Jan 2021 | CN |
| 113230486 | Aug 2021 | CN |
| 113613616 | Nov 2021 | CN |
| 113645935 | Nov 2021 | CN |
| 114450047 | May 2022 | CN |
| 2125099 | Mar 2011 | DK |
| 2654938 | Nov 2014 | DK |
| 3010568 | May 2019 | DK |
| 2723426 | Nov 2019 | DK |
| 3274020 | Apr 2021 | DK |
| 1391219 | Feb 2004 | EP |
| 2094340 | Sep 2009 | EP |
| 2121112 | Nov 2009 | EP |
| 2125099 | Dec 2009 | EP |
| 2331190 | Jun 2011 | EP |
| 2376141 | Oct 2011 | EP |
| 2438339 | Apr 2012 | EP |
| 2654938 | Oct 2013 | EP |
| 2723426 | Apr 2014 | EP |
| 2877763 | Jun 2015 | EP |
| 2902002 | Aug 2015 | EP |
| 2968770 | Jan 2016 | EP |
| 3010568 | Apr 2016 | EP |
| 3025056 | Jun 2016 | EP |
| 3025057 | Jun 2016 | EP |
| 3025058 | Jun 2016 | EP |
| 3035903 | Jun 2016 | EP |
| 3082419 | Oct 2016 | EP |
| 3099282 | Dec 2016 | EP |
| 3183015 | Jun 2017 | EP |
| 3183016 | Jun 2017 | EP |
| 3183019 | Jun 2017 | EP |
| 3183020 | Jun 2017 | EP |
| 3233061 | Oct 2017 | EP |
| 3268068 | Jan 2018 | EP |
| 3274020 | Jan 2018 | EP |
| 3313478 | May 2018 | EP |
| 3325049 | May 2018 | EP |
| 3592405 | Jan 2020 | EP |
| 3634357 | Apr 2020 | EP |
| 3638186 | Apr 2020 | EP |
| 3682920 | Jul 2020 | EP |
| 3694582 | Aug 2020 | EP |
| 3697367 | Aug 2020 | EP |
| 3706909 | Sep 2020 | EP |
| 3870132 | Sep 2021 | EP |
| 3890805 | Oct 2021 | EP |
| 3906002 | Nov 2021 | EP |
| 3909623 | Nov 2021 | EP |
| 4003459 | Jun 2022 | EP |
| 2357478 | Apr 2011 | ES |
| 2524695 | Dec 2014 | ES |
| 2597736 | Jan 2017 | ES |
| 2627978 | Aug 2017 | ES |
| 2629412 | Aug 2017 | ES |
| 2644817 | Nov 2017 | ES |
| 2656768 | Feb 2018 | ES |
| 2728054 | Oct 2019 | ES |
| 2753031 | Apr 2020 | ES |
| 2784517 | Sep 2020 | ES |
| 2784680 | Sep 2020 | ES |
| 2867775 | Oct 2021 | ES |
| 2909001 | May 2008 | FR |
| 2912919 | Aug 2008 | FR |
| 2934500 | Feb 2010 | FR |
| 2936160 | Mar 2010 | FR |
| 2946408 | Dec 2010 | FR |
| 2933872 | Jan 2012 | FR |
| 2969507 | Jun 2012 | FR |
| 2993791 | Jan 2014 | FR |
| 2998365 | May 2014 | FR |
| 3008744 | Jan 2015 | FR |
| 3008745 | Jan 2015 | FR |
| 3008746 | Jan 2015 | FR |
| 3092001 | Jul 2020 | FR |
| 3106765 | Aug 2021 | FR |
| 3106865 | Aug 2021 | FR |
| 3110392 | Nov 2021 | FR |
| E043627 | Sep 2019 | HU |
| E054394 | Sep 2021 | HU |
| 198849 | Jun 2011 | IL |
| 200263 | Jul 2013 | IL |
| 201717008723 | Jul 2017 | IN |
| 201717008752 | Jul 2017 | IN |
| 201717008825 | Aug 2017 | IN |
| 201717008826 | Aug 2017 | IN |
| 201717025457 | Nov 2017 | IN |
| 201717040205 | Dec 2017 | IN |
| 201817003834 | Apr 2018 | IN |
| 2010-510012 | Apr 2010 | JP |
| 2010-518951 | Jun 2010 | JP |
| 5093822 | Dec 2012 | JP |
| 5143849 | Feb 2013 | JP |
| 2014-503280 | Feb 2014 | JP |
| 2014-523296 | Sep 2014 | JP |
| 6560187 | Sep 2014 | JP |
| 5755164 | Jul 2015 | JP |
| 2015-524303 | Aug 2015 | JP |
| 5882358 | Mar 2016 | JP |
| 2016-512148 | Apr 2016 | JP |
| 2016-524513 | Aug 2016 | JP |
| 2016-525182 | Aug 2016 | JP |
| 2016-525645 | Aug 2016 | JP |
| 2016-525647 | Aug 2016 | JP |
| 2017-503017 | Jan 2017 | JP |
| 2017-504430 | Feb 2017 | JP |
| 6122496 | Apr 2017 | JP |
| 2017-525469 | Sep 2017 | JP |
| 2017-525470 | Sep 2017 | JP |
| 2017-525471 | Sep 2017 | JP |
| 2017-525472 | Sep 2017 | JP |
| 2017-538731 | Dec 2017 | JP |
| 2018-509252 | Apr 2018 | JP |
| 6345590 | Jun 2018 | JP |
| 2018-517536 | Jul 2018 | JP |
| 2018-522654 | Aug 2018 | JP |
| 2018-522684 | Aug 2018 | JP |
| 2018-153672 | Oct 2018 | JP |
| 6456479 | Jan 2019 | JP |
| 6462859 | Jan 2019 | JP |
| 2019-055286 | Apr 2019 | JP |
| 2019-065043 | Apr 2019 | JP |
| 6525445 | Jun 2019 | JP |
| 6580777 | Sep 2019 | JP |
| 2019-166407 | Oct 2019 | JP |
| 2019-188174 | Oct 2019 | JP |
| 6594410 | Oct 2019 | JP |
| 2019-195670 | Nov 2019 | JP |
| 6606274 | Nov 2019 | JP |
| 2019-217323 | Dec 2019 | JP |
| 6616840 | Dec 2019 | JP |
| 2020-032240 | Mar 2020 | JP |
| 2020-510486 | Apr 2020 | JP |
| 6691041 | Apr 2020 | JP |
| 2020-110665 | Jul 2020 | JP |
| 2020-521540 | Jul 2020 | JP |
| 2020-523131 | Aug 2020 | JP |
| 2020-536658 | Dec 2020 | JP |
| 2020-536660 | Dec 2020 | JP |
| 2021-063134 | Apr 2021 | JP |
| 2021-510550 | Apr 2021 | JP |
| 2021-073311 | May 2021 | JP |
| 2021-130002 | May 2021 | JP |
| 6882377 | Jun 2021 | JP |
| 2021-191465 | Dec 2021 | JP |
| 2022-024075 | Feb 2022 | JP |
| 2022-512039 | Feb 2022 | JP |
| 7000443 | Feb 2022 | JP |
| 2022-516608 | Mar 2022 | JP |
| 7030762 | Mar 2022 | JP |
| 7036910 | Mar 2022 | JP |
| 7053709 | Apr 2022 | JP |
| 2022-068324 | May 2022 | JP |
| 7063920 | May 2022 | JP |
| 2022-084917 | Jun 2022 | JP |
| 2022-101639 | Jul 2022 | JP |
| 2009-0076984 | Jul 2009 | KR |
| 2009-0113866 | Nov 2009 | KR |
| 101070203 | Oct 2011 | KR |
| 101213003 | Dec 2012 | KR |
| 2013-0133255 | Dec 2013 | KR |
| 2016-0033131 | Mar 2016 | KR |
| 2016-0045710 | Apr 2016 | KR |
| 2016-0045711 | Apr 2016 | KR |
| 2016-0135182 | Nov 2016 | KR |
| 101871701 | Jul 2018 | KR |
| 101882723 | Jul 2018 | KR |
| 2125099 | Mar 2011 | PL |
| 200836786 | Sep 2008 | TW |
| 200902109 | Jan 2009 | TW |
| I417117 | Dec 2013 | TW |
| WO 96036429 | Nov 1996 | WO |
| WO 02067814 | Sep 2002 | WO |
| WO 2008051925 | May 2008 | WO |
| WO 2008062032 | May 2008 | WO |
| WO 2008101892 | Aug 2008 | WO |
| WO 2010007296 | Jan 2010 | WO |
| WO 2010015770 | Feb 2010 | WO |
| WO 2010031974 | Mar 2010 | WO |
| WO 2010139913 | Dec 2010 | WO |
| WO 2012085428 | Jun 2012 | WO |
| WO 2014016479 | Jan 2014 | WO |
| WO 2014076419 | May 2014 | WO |
| WO 2014145959 | Sep 2014 | WO |
| WO 2014146060 | Sep 2014 | WO |
| WO 2015009871 | Jan 2015 | WO |
| WO 2015011352 | Jan 2015 | WO |
| WO 2015011353 | Jan 2015 | WO |
| WO 2015011384 | Jan 2015 | WO |
| WO 2015095624 | Jun 2015 | WO |
| WO 2015107214 | Jul 2015 | WO |
| WO 2015113897 | Aug 2015 | WO |
| WO 2016028814 | Feb 2016 | WO |
| WO 2016028815 | Feb 2016 | WO |
| WO 2016028817 | Feb 2016 | WO |
| WO 2016028820 | Feb 2016 | WO |
| WO 2016100949 | Jun 2016 | WO |
| WO 2016166339 | Oct 2016 | WO |
| WO 2016190980 | Dec 2016 | WO |
| WO 2017014847 | Jan 2017 | WO |
| WO 2017027876 | Feb 2017 | WO |
| WO 2017062005 | Apr 2017 | WO |
| WO 2018085318 | May 2018 | WO |
| WO 2018165588 | Sep 2018 | WO |
| WO 2018218082 | Nov 2018 | WO |
| WO 2018232171 | Dec 2018 | WO |
| WO 2019011870 | Jan 2019 | WO |
| WO 2019075337 | Apr 2019 | WO |
| WO 2019079335 | Apr 2019 | WO |
| WO 2019094547 | May 2019 | WO |
| WO 2020086581 | Apr 2020 | WO |
| WO 2020142544 | Jul 2020 | WO |
| WO 2020152424 | Jul 2020 | WO |
| WO 2020180081 | Sep 2020 | WO |
| WO 2020180507 | Sep 2020 | WO |
| WO 2020217170 | Oct 2020 | WO |
| WO 2020240417 | Dec 2020 | WO |
| WO 2021016567 | Jan 2021 | WO |
| WO 2021156573 | Aug 2021 | WO |
| WO 2021156574 | Aug 2021 | WO |
| WO 2021234306 | Nov 2021 | WO |
| WO 2021243341 | Dec 2021 | WO |
| WO 2022006063 | Jan 2022 | WO |
| WO 2022031784 | Feb 2022 | WO |
| Entry |
|---|
| U.S. Appl. No. 29/843,616, filed Jun. 22, 2022, Sherman et al. |
| International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/IB2021/062218, dated Apr. 7, 2022, 18 pages. |
| Article 94(3) Communication for Europe Patent Application No. 21840159.4, dated Jan. 31, 2023, 10 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20220331523 A1 | Oct 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63130144 | Dec 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/IB2021/062218 | Dec 2021 | US |
| Child | 17854769 | US |
